Navigation Links
Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Date:11/1/2012

TITUSVILLE, N.J., Nov. 1, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV). The regimen will include Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue HCV polymerase inhibitor VX-135. As a first step, Janssen will conduct a drug-drug interaction (DDI) study with simeprevir and VX-135. The DDI study will support the initiation of the Phase 2 study in early 2013 pending discussions with regulatory authorities.

The goal of the Phase 2 study will be to evaluate the safety, tolerability and viral cure rates of a 12-week regimen of simeprevir and VX-135, administered with and without ribavirin, in treatment-naive patients who have chronic non-cirrhotic genotype 1 HCV. The companies will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.

Simeprevir is an investigational NS3/4A protease inhibitor currently in Phase 3 trials, developed in collaboration with and licensed from Medivir AB. VX-135 is an investigational uridine nucleotide analogue pro-drug designed to inhibit the replication of HCV by acting on the NS5B polymerase. 

"There is a significant unmet need for all-oral treatment regimens for people living with hepatitis C," said Wim Parys, Global Head of Infectious Diseases at Janssen. "Janssen's collaboration with Vertex underscores our commitment to better understand the potential utility of simeprevir in a number of different interferon-free treatment combinations and HCV patient populations."

About Simeprevir
Simeprevir (TMC435) is an NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB to treat chronic HCV infection. Simepr
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. Watson Announces Global Generics Management Team
8. Watson Announces New Name -- Actavis -- for Global Operations
9. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014 Baptist Health Lexington is ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) ... Atrial fibrillation is the most common cardiac arrhythmia ... some cases can lead to stroke and possible death. More ... have atrial fibrillation and the numbers are rapidly ...
(Date:12/19/2014)... , Dec. 18, 2014   Aratana ... a biopharmaceutical company focused on the licensing, development ... today announced positive results from its pivotal field ... for treating pain in dogs with osteoarthritis.  In ... pain assessment scores that were statistically significant compared ...
(Date:12/19/2014)... market has witnessed robust development with the growth pace keeping ... starter. In 2012, the size of China ... proportion worldwide soaring to 16.3%. It is projected that ... growth rate by around 20% in the upcoming years and ... billion. An integrated membrane industrial system has taken ...
Breaking Medicine Technology:Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... Va., March 16 Innocoll, Inc., a privately-held ... been dosed in the first of two ongoing ... wholly owned subsidiary, Innocoll Technologies Ltd, to investigate ... surgical site infections.The trial is being conducted at ...
... 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... that identifies, develops and commercializes differentiated products ... poster entitled, "Binding properties of the anti-EGFR ... EGFR in renal and epidermal cells", has ...
Cached Medicine Technology:Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 2Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients 3YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 3YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 5
(Date:12/22/2014)... News) -- A new vaccine created to fight an ... also protect livestock and even humans from similar brain ... prevent deer from becoming infected by the incurable brain ... report in the Dec. 21 online edition of the ... by mysterious infectious particles known as prions that go ...
(Date:12/22/2014)... 2014 Super Saturday, the last Saturday ... as the busiest day in the 2014 holiday shopping ... Station had a steady pre-Christmas stream of customers, ready ... Saturday. , “I definitely intend to take advantage…of the ... resident who was enjoying The Grass Station’s holiday sale ...
(Date:12/22/2014)... Give a loved one the greatest gift ... and vitality. , For a limited time, HealthiPlus ( ... in special Holiday Wellness gift packages at drastically reduced ... bottle contains cutting-edge, proven nutritional support for joints, mental ... as we age. , Joint Health Plus ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 TheHardwareCity.com now ... glove with many useful features. Customers of the large ... have the new gloves delivered to their home or ... and hand tools that incorporate heavy duty magnets, which ... Glove allows workers to store metal parts on the ...
Breaking Medicine News(10 mins):Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... PENSACOLA, Fla., Sept. 24 In these economically challenging times, ... Better overall health means lower medical bills. , ... took two weeks of vacation last year, and the number of ... past generation. The price Americans are paying, by not getting away ...
... , JERSEY CITY, N.J., Sept. 24 ... the health website QualityHealth.com , has today filed ... MTS,s intellectual property rights and misappropriated trade secrets and other confidential ... RemedyLife.com , a health website owned and operated ...
... created a new approach that vastly improves the ... organs. Kenneth Longmuir, associate professor of physiology ... & neurobiology, used liposomes, small spheres (less-than 100 ... "packages" for the cancer chemotherapeutic agent doxorubicin, and ...
... build up during waking hours, , THURSDAY, Sept. 24 (HealthDay ... a little harder to get a good night,s sleep, now ... keep Alzheimer,s disease at bay. , The research was conducted ... to humans. Still, the possible link between sleep deprivation and ...
... , NEW YORK, Sept. 24 Reportlinker.com ... in its catalogue. , , ... Profiles, Implications for Immunoassays and Molecular Assays) ... , The outbreak of swine flu ...
... OAKLAND, Calif., Sept. 24 A new national opinion poll conducted ... more than half (56%) of Hispanic adults polled said they were ... than four in ten indicated that they were "very likely" to ... To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/clorox/40141/ ...
Cached Medicine News:Health News:Health-Related Tourism Catching On 2Health News:MediZine Named in Intellectual Property Lawsuit Filed by Marketing Technology Solutions 2Health News:UCI researchers create new strategy for highly-selective chemotherapy delivery 2Health News:Sleep Deprivation Might Lead to Alzheimer's 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 3Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 4Health News:Video: Despite Increased Health Threat, New Study Finds Low Concern About Flu Among Hispanics 2
... The GENIE is the proven electrophoretic transfer ... in field uniformity. Its design allows for a ... coupled with a low voltage power source such ... in volts/cm. The result is exceptionally rapid and ...
... Trans-Blot cell, a component of Bio-Rad's modular ... provides rapid, high-quality blotting of mini gels. ... x 10 cm gels in just 1 ... cooling unit, which absorbs heat generated during ...
... Includes PowerPac 200 power ... Range of Parameters. Quantitative Transfers. ... or Overnight Transfers. Faster, ... High Field-Intensity Transfers with ...
... gel holder cassettes, cell with ... pads, blot absorbent paper (15 ... transfer cell, used with the ... efficient, high-intensity electrophoretic transfers. The ...
Medicine Products: